MedImmune and Celgene to collaborate on anti-PD-L1 inhibitor programme for haematological malignancies

MedImmune, a subsidiary of AstraZeneca PLC, and Celgene are collaborating on a programme to develop and commercialise an anti-PD-L1 inhibitor, MEDI4736, for the treatment of myeloma and other haematological malignancies. MEDI4736 is a human anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody which works as an immune checkpoint inhibitor and enables the immune system to…

Details